RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
G1 Therapeutics Stock

G1 Therapeutics Liabilities 2024

G1 Therapeutics Liabilities

86.15 M USD

Ticker

GTHX

ISIN

US3621LQ1099

WKN

A2DR0J

In 2024, G1 Therapeutics's total liabilities amounted to 86.15 M USD, a -27.72% difference from the 119.2 M USD total liabilities in the previous year.

G1 Therapeutics Aktienanalyse

What does G1 Therapeutics do?

G1 Therapeutics Inc is a biopharmaceutical company that was founded in 2008 and is headquartered in Research Triangle Park, North Carolina, USA. The company specializes in the treatment of cancer and is dedicated to improving the quality of life for cancer patients. G1 Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing G1 Therapeutics's Liabilities

G1 Therapeutics's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating G1 Therapeutics's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing G1 Therapeutics's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

G1 Therapeutics's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in G1 Therapeutics’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about G1 Therapeutics stock

What is the level of liabilities of G1 Therapeutics this year?

G1 Therapeutics has a debt balance of 86.15 M USD this year.

What were the liabilities of G1 Therapeutics compared to the previous year?

The liabilities of G1 Therapeutics have increased by -27.72% dropped compared to the previous year.

What are the consequences of high debt for investors of G1 Therapeutics?

High liabilities can pose a risk for investors of G1 Therapeutics, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in G1 Therapeutics?

Low liabilities mean that G1 Therapeutics has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of G1 Therapeutics affect the company?

An increase in liabilities of G1 Therapeutics can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of G1 Therapeutics affect the company?

A decrease in the liabilities of G1 Therapeutics can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of G1 Therapeutics?

Some factors that can influence the liabilities of G1 Therapeutics include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of G1 Therapeutics so important for investors?

The liabilities of G1 Therapeutics are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can G1 Therapeutics take to modify the liabilities?

To change its liabilities, G1 Therapeutics can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does G1 Therapeutics pay?

Over the past 12 months, G1 Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, G1 Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of G1 Therapeutics?

The current dividend yield of G1 Therapeutics is .

When does G1 Therapeutics pay dividends?

G1 Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of G1 Therapeutics?

G1 Therapeutics paid dividends every year for the past 0 years.

What is the dividend of G1 Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is G1 Therapeutics located?

G1 Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von G1 Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of G1 Therapeutics from 12/17/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 12/17/2024.

When did G1 Therapeutics pay the last dividend?

The last dividend was paid out on 12/17/2024.

What was the dividend of G1 Therapeutics in the year 2023?

In the year 2023, G1 Therapeutics distributed 0 USD as dividends.

In which currency does G1 Therapeutics pay out the dividend?

The dividends of G1 Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von G1 Therapeutics

Our stock analysis for G1 Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of G1 Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.